Return to site

Osmolex ER Will Help Patients with Parkinson’s Disease

Thompson Dean

A graduate of the Harvard Business School, Thompson Dean is the CEO and cofounder of Avista Capital Partners, a private equity firm with a focus on the healthcare industry. Under Thompson Dean’s leadership, Avista Capital Partners has developed a deep understanding of trends within the healthcare industry, guiding the firm to a sound investment strategy in pharmaceuticals, medical devices, distribution, and consumer-driven healthcare. Recently, Osmotica Pharmaceutical received FDA approval for Osmolex ER, a drug used to treat Parkinson’s disease.

Parkinson’s disease affects up to 1 million people in the United States. The slow-progressing disease is a neurodegenerative disorder that affects a part of the brain called the substantia nigra. It leaves patients with tremors, slow movements, and balance problems. Often, doctors recommend treatment utilizing levodopa, a dopamine inhibiter; while an important part of treating Parkinson’s, this medication can cause dyskinesia, or involuntary and erratic movements.
Osmolex ER was developed to help relieve the symptoms of Parkinson’s disease as well as other involuntary movement disorders. The medication uses Osmotica Pharmaceutical’s proprietary osmotic drug delivery platform, which simplifies dosing. The manufacturers of FDA-approved, once-daily Osmolex ER are currently commercializing the medication and making it accessible to patients suffering from Parkinson’s disease.

All Posts

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!

OKSubscriptions powered by Strikingly